Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intérêt de l'IL-26 Comme Nouveau Marqueur Biologique du Lupus érythémateux systémique

NCT01889641 is registered in ClinicalTrials.gov with University Hospital, Strasbourg, France as lead sponsor.

NCT NCT01889641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01889641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intérêt de l'IL-26 Comme Nouveau Marqueur Biologique du Lupus érythémateux systémique
Lead sponsor
University Hospital, Strasbourg, France
Phase
Observational
Overall status
Terminated
Start date
February 28, 2014
Completion date
April 30, 2015
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diagnosis of lupus according to acr criteriaagreement for the blood sampling